Acerand Therapeutics (USA) Ltd. has identified fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of cancer.

Acerand Therapeutics (USA) Ltd. has discovered new son of sevenless homologue 1 (SOS1)/GTPase KRAS (G12D mutant) interaction inhibitors reported to be useful for the treatment of cancer.